細胞外小胞:バイオゲネシスメカニズムと腫瘍免疫マイクロ環境への影響
PubMedで要約を見る
まとめ
この要約は機械生成です。細胞外ベシクル (EV) は,生物活性物質の伝達によって細胞の伝達を媒介する. このレビューでは,非典型型を含むEVが腫瘍の免疫マイクロ環境 (TIME) をどのように調節し,がんの診断と治療におけるその可能性を調査します.
科学分野
- 細胞生物学
- 免疫学
- 腫瘍学
背景
- 細胞外ベシクル (EV) は細胞間通信の重要な媒介体であり,様々な生物活性分子を運びます.
- EVの負荷と生殖は細胞環境と特定の分子調節因子によって影響を受けます.
- 腫瘍免疫マイクロ環境 (TIME) は,EVが重要な役割を果たす複雑なネットワークです.
研究 の 目的
- EVの生体生成,分泌,そして TIMEの調節におけるその多面的な役割を見直す.
- 腫瘍由来および免疫細胞由来EVが癌の進行と免疫回避に与える影響を要約する.
- 癌の診断と治療におけるEVの臨床応用を強調する.
主な方法
- EVの生体生成,機能,臨床応用に焦点を当てた文献レビュー.
- 腫瘍の免疫微環境におけるEV媒介によるコミュニケーションを詳細に記述した研究の分析.
- 非典型のEVと癌におけるその特定の役割に関する研究の検討.
主要な成果
- EVは TIME内の免疫細胞のフェノタイプを調節し,免疫逃避を促進する.
- 免疫細胞に由来するEVは,腫瘍細胞の悪性腫瘍に影響を与える.
- 非典型のEVは TIMEの中でユニークな規制機能を示します.
- EVは癌の検出のための液体生検として有望です.
- EVはがん治療の薬媒介として研究されており,臨床試験も進行中です.
結論
- EVは癌の生物学における重要な役割を果たし,TIMEに影響を与え,診断と治療の可能性を秘めています.
- EVのメカニズムと技術的進歩のさらなる理解は,その完全な生物医学的な応用を開くでしょう.
- 新しいがん治療法や診断ツールの開発において 電気自動車は有望な先駆けとなります
関連する概念動画
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
After budding out from the ER membrane, some COPII vesicles lose their coat and fuse with one another to form larger vesicles and interconnected tubules called vesicular tubular clusters or VTCs. These clusters constitute a compartment at the ER-Golgi interface known as ERGIC (Endoplasmic Reticulum Golgi Intermediate Compartment). The ERGIC is a mobile membrane-bound cargo transport system that sorts proteins secreted from ER and delivers them to the Golgi.
With the help of motor proteins such...
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

